Leiomyosarcoma natural history: Difference between revisions
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Leiomyosarcoma most commonly metastasizes to the lungs, liver, abdomen, pelvis, and pelvic or paraaortic lymph nodes.<ref name="pmid24834891">Cooley CL, Jagannathan JP, Kurra V, Tirumani SH, Saboo SS, Ramaiya NH et al. (2014) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=24834891 Imaging features and metastatic pattern of non-IVC retroperitoneal leiomyosarcomas: are they different from IVC leiomyosarcomas?] ''J Comput Assist Tomogr'' 38 (5):687-92. [http://dx.doi.org/10.1097/RCT.0000000000000097 DOI:10.1097/RCT.0000000000000097] PMID: [https://pubmed.gov/24834891 24834891]</ref>Bone and brain metastases are less common sites of involvement.<ref name="pmid8281375">{{cite journal| author=Moskovic E, MacSweeney E, Law M, Price A| title=Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients. | journal=Br J Radiol | year= 1993 | volume= 66 | issue= 791 | pages= 1009-15 | pmid=8281375 | doi=10.1259/0007-1285-66-791-1009 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8281375 }}</ref>Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor.Overall survival rate ranges from 15% to 25% with a median survival of only 10 months. | [[Leiomyosarcoma]] most commonly metastasizes to the [[lungs]], [[liver,]] [[abdomen]], [[pelvis]], and pelvic or paraaortic lymph nodes.<ref name="pmid24834891">Cooley CL, Jagannathan JP, Kurra V, Tirumani SH, Saboo SS, Ramaiya NH et al. (2014) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=24834891 Imaging features and metastatic pattern of non-IVC retroperitoneal leiomyosarcomas: are they different from IVC leiomyosarcomas?] ''J Comput Assist Tomogr'' 38 (5):687-92. [http://dx.doi.org/10.1097/RCT.0000000000000097 DOI:10.1097/RCT.0000000000000097] PMID: [https://pubmed.gov/24834891 24834891]</ref>Bone and brain metastases are less common sites of involvement.<ref name="pmid8281375">{{cite journal| author=Moskovic E, MacSweeney E, Law M, Price A| title=Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients. | journal=Br J Radiol | year= 1993 | volume= 66 | issue= 791 | pages= 1009-15 | pmid=8281375 | doi=10.1259/0007-1285-66-791-1009 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8281375 }}</ref>Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor.Overall survival rate ranges from 15% to 25% with a median survival of only 10 months. | ||
==Natural History== | ==Natural History== | ||
Revision as of 04:43, 15 July 2018
|
Leiomyosarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Leiomyosarcoma natural history On the Web |
|
American Roentgen Ray Society Images of Leiomyosarcoma natural history |
|
Risk calculators and risk factors for Leiomyosarcoma natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Leiomyosarcoma most commonly metastasizes to the lungs, liver, abdomen, pelvis, and pelvic or paraaortic lymph nodes.[1]Bone and brain metastases are less common sites of involvement.[2]Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor.Overall survival rate ranges from 15% to 25% with a median survival of only 10 months.
Natural History
Most Leiomyosarcoma are diagnosed incidentally at an advanced stage. A leiomyosarcoma, especially in the early stages, may not be associated with any obvious symptoms (asymptomatic).The majority of patients with leiomyosarcoma remain asymptomatic for decades. General symptoms associated with cancer may occur including fatigue, fever, weight loss, a general feeling of ill health (malaise), and nausea and vomiting.
Complications
They are invariably aggressive that may metastasize to other areas of the body such as the lungs or liver, potentially causing life-threatening complications. Leiomyosarcoma has a high risk of recurring of about 53% to 71% after treatment, if not diagnosed early.[3]
Prognosis
The prognosis of leiomyosarcoma[4] is poor and it depends on varying factors:"Leiomyosarcoma - Survival Rate, Symptoms, Prognosis, Treatment - CancerWall.com - Cancers & Tumors Information, Research & More".
- Tumor size
- Tumor location
- Tumor type/Grade[5]
- DNA content
- Hormonal receptor status
- cellular division and mitotic rate
- local and distant extension
- Whether or not the tumor can be removed by surgery
- The patient’s general health
Survival Rate of Leiomyosarcoma by staging:
| Stage | Percentage |
| stage 1 | 60 |
| stage 2 | 35 |
| stage 3 | 28 |
| stage 4 | 15 |
References
- ↑ Cooley CL, Jagannathan JP, Kurra V, Tirumani SH, Saboo SS, Ramaiya NH et al. (2014) Imaging features and metastatic pattern of non-IVC retroperitoneal leiomyosarcomas: are they different from IVC leiomyosarcomas? J Comput Assist Tomogr 38 (5):687-92. DOI:10.1097/RCT.0000000000000097 PMID: 24834891
- ↑ Moskovic E, MacSweeney E, Law M, Price A (1993). "Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients". Br J Radiol. 66 (791): 1009–15. doi:10.1259/0007-1285-66-791-1009. PMID 8281375.
- ↑ Gadducci A (2011) Prognostic factors in uterine sarcoma. Best Pract Res Clin Obstet Gynaecol 25 (6):783-95. DOI:10.1016/j.bpobgyn.2011.06.002 PMID: 21764643
- ↑ Schwartz Z, Dgani R, Lancet M, Kessler I (1985) Uterine sarcoma in Israel: a study of 104 cases. Gynecol Oncol 20 (3):354-63. PMID: 2982707
- ↑ Giuntoli RL, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL et al. (2003) Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 89 (3):460-9. PMID: 12798712